SecurityIPAS / iPass, Inc. (46261V108)
Institutional Owners37
Institutional Shares22,835,821 - 31.39%
Common Shares Outstanding72,745,276 shares (as of 2018-03-31)
Institutional Value$ 5,232,000 USD

Institutional Stock Ownership and Shareholders

IPAS / iPass, Inc. Institutional Ownership

iPass, Inc. (NASDAQ:IPAS) has 37 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 22,835,821 shares. Largest shareholders include C. Silk & Sons, Inc., Renaissance Technologies LLC, Leviticus Partners L P, Vanguard Group Inc, Pratt Collard Advisory Partners Llc, Royce & Associates LLC, Adirondack Research & Management Inc., Goldman Capital Management Inc, Eidelman Virant Capital, and Geode Capital Management, Llc.
iPass, Inc. (NASDAQ:IPAS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/ipas"><img src="https://images.fintel.io/us-ipas-so.png" alt="IPAS / iPass, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-02-14 13F-HR DEUTSCHE BANK AG\ 13,400 0 -100.00 8 0 -100.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 0 0 0 0
2018-05-14 13F-HR/A KEYBANK NATIONAL ASSOCIATION/OH 40,000 0 -100.00 26 0 -100.00
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 99,900 99,900 0.00 52 38 -26.92
2018-02-15 13F-HR Sterling Capital Management LLC 75,000 0 -100.00 49 0 -100.00
2018-05-15 13F-HR UBS Group AG 114 22,525 19,658.77 0 8
2018-01-24 13F-HR FNY Partners Fund LP 45,000 0 -100.00 29 0 -100.00
2018-05-14 13F-HR Commonwealth Equity Services, Llc. 38,738 48,738 25.81 20 18 -10.00
2018-05-11 13F-HR M&R CAPITAL MANAGEMENT INC 15,000 15,000 0.00 7 5 -28.57
2018-05-15 13F-HR Advisor Group, Inc. 20,000 0 -100.00 10 0 -100.00
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 0 26,934 0 10
2018-02-08 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 6,476 0 -100.00 4 0 -100.00
2018-02-12 13F-HR DIMENSIONAL FUND ADVISORS LP 254,367 0 -100.00 168 0 -100.00
2018-04-19 13F-HR Mccollum Christoferson Group Llc 40,000 40,000 0.00 21 15 -28.57
2018-05-11 13F-HR Emancipation Management LLC 50,000 0 -100.00 26 0 -100.00
2018-05-15 13F-HR Capital Bank & Trust Co 7,035 7,035 0.00 4 3 -25.00
2018-05-15 13F-HR JACOBS LEVY EQUITY MANAGEMENT, INC 132,903 452,065 240.15 69 172 149.28
2018-05-14 13F-HR WHITE PINE CAPITAL LLC 35,000 35,000 0.00 18 13 -27.78
2018-05-14 13F-HR NOMURA HOLDINGS INC 82,452 37
2018-05-14 13F-HR UNITED SERVICES AUTOMOBILE ASSOCIATION 12,564 5
2018-05-15 13F-HR GUGGENHEIM CAPITAL LLC 21,100 23,735 12.49 11 9 -18.18
2018-02-01 13F-HR Abbrea Capital, LLC 341,000 0 -100.00 225 0 -100.00
2018-05-09 13F-HR NORTHERN TRUST CORP 134,197 134,197 0.00 69 51 -26.09
2018-05-15 13F-HR STATE STREET CORP 27,610 27,610 0.00 13 10 -23.08
2018-02-14 13F-HR GOLDMAN CAPITAL MANAGEMENT INC 1,301,000 801,000 -38.43 859 417 -51.46
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 474,363 474,363 0.00 246 180 -26.83
2018-05-09 13F-HR GABELLI FUNDS LLC 100,000 50,000 -50.00 52 19 -63.46
2018-04-20 13F-HR Pratt Collard Advisory Partners Llc 1,808,620 1,654,520 -8.52 940 629 -33.09
2018-04-18 13F-HR Creative Planning 30,000 30,000 0.00 16 11 -31.25
2018-05-14 13F-HR Renaissance Technologies LLC 3,267,698 3,291,898 0.74 1,699 1,251 -26.37
2018-05-14 13F-HR Royce & Associates LLC 948,500 948,500 0.00 493 360 -26.98
2018-04-24 13F-HR Paragon Capital Management Ltd 16,667 16,667 0.00 9 6 -33.33
2018-05-14 13F-HR Adirondack Research & Management Inc. 1,127,363 814,742 -27.73 586 310 -47.10
2018-04-19 13F-HR Eidelman Virant Capital 650,000 247
2018-01-03 SC 13G/A C. Silk & Sons, Inc. 6,022,770 6,449,825 7.09
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 38,738 38,738 0.00 51 26 -49.02
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 54 0 -100.00 0 0
2018-02-14 13F-HR TWO SIGMA SECURITIES, LLC 23,831 0 -100.00 16 0 -100.00
2018-05-15 13F-HR VANGUARD GROUP INC 2,313,037 2,297,739 -0.66 1,203 873 -27.43
2018-05-15 13F-HR EARNEST PARTNERS LLC 7,700 7,700 0.00 4 3 -25.00
2018-05-15 13F-HR Manatuck Hill Partners, LLC 450,000 171
2018-05-15 13F-HR Bank of New York Mellon Corp 53,977 66,541 23.28 28 26 -7.14
2018-05-14 13F-HR MORGAN STANLEY 104 61 -41.35 0 0
2018-02-14 13F-HR MILLENNIUM MANAGEMENT LLC 330,000 0 -100.00 218 0 -100.00
2018-05-15 13F-HR One Wealth Advisors, Llc 76,700 76,700 0.00 40 29 -27.50
2018-05-09 13F-HR BlackRock Inc. 311,743 295,997 -5.05 163 112 -31.29
2018-02-14 SC 13G/A Millennium Technology Value Partners RCM L P 5,550,005
2018-04-16 13F-HR AMG National Trust Bank 29,570 49,570 67.64 15 19 26.67
2018-05-14 13F-HR Virtu Financial LLC 36,594 0 -100.00 19 0 -100.00
2018-01-30 13F-HR P.A.W. CAPITAL CORP 500,000 0 -100.00 330 0 -100.00
2018-02-14 13F-HR Millennium TVP Management Co., LLC 5,383,769 0 -100.00 3,553 0 -100.00
2018-01-17 SC 13G/A LEVITICUS PARTNERS L P 3,616,096 2,950,000 -18.42
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 351,470 351,470 0.00 183 134 -26.78
2018-05-11 13F-HR MACQUARIE GROUP LTD 60,245 0 -100.00 31 0 -100.00
2018-05-07 13F-HR Marathon Capital Management 42,035 15

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

iPass' (IPAS) CEO Gary Griffiths on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Good day. And welcome to the iPass First Quarter 2018 Financial Results Conference Call. Today's conference is being recorded. (15-0)

iPass Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-09 seekingalpha
The following slide deck was published by iPass Inc. in conjunction with their 2018 Q1 earnings call. (15-1)

BRIEF-Ipass Announces A Deal With Lycamobile To Provide Global Wi-Fi To Its Monthly Plan Customers

2018-04-16 reuters
* IPASS INC - ANNOUNCED A DEAL WITH LYCAMOBILE TO PROVIDE GLOBAL WI-FI TO ITS MONTHLY PLAN CUSTOMERS (15-4)

iPass' (IPAS) CEO Gary Griffiths on Q4 2017 Results - Earnings Call Transcript

2018-02-22 seekingalpha
Good day, and welcome to the iPass Fourth Quarter and Fiscal and Year-End 2017 Financial Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Ms. Kirsten Chapman, LHA Investor Relations. Please go ahead, ma'am. (15-2)

iPass Inc. 2017 Q4 - Results - Earnings Call Slides

2018-02-21 seekingalpha
The following slide deck was published by iPass Inc. in conjunction with their 2017 Q4 earnings call. (15-1)

CUSIP: 46261V108